Literature DB >> 31721038

Benefits, risks and impacts on quality of life of medications used in multimorbid older adults: a Delphi study.

Caroline Sirois1,2,3, Carlotta Lunghi4, William Berthelot5, Marie-Laure Laroche6,7,8, Anissa Frini9.   

Abstract

Background Multimorbidity and polypharmacy are common in older people. Despite the existence of quality criteria for medication use among this population, there is little guidance for managing the complex pharmacological arsenal in a multimorbidity context. Objective To establish consensus on benefits, risks and impacts on quality of life of medications used in an older adult with three chronic diseases that require complex pharmacotherapy. Setting International experts in pharmacology. Method A panel of experts responded to three rounds of a Delphi survey. They assessed the benefits, risks and positive impacts on quality of life of 50 different medications or medication classes that could be used by a hypothetical multimorbid older patient aged 65-75 years, with type 2 diabetes, heart failure and chronic obstructive pulmonary disease. Each aspect was evaluated on a 5-level Likert scale. Main outcome measure Percentage of agreement on each of the three aspects for all medication. Results Consensus was reached on 95% of items (166/174). Only two medication classes were associated with both the highest category of benefits and positive impacts on quality of life, and the lowest risk category: long-acting anticholinergics and long-acting beta-2-agonists. Nine other medications/classes of medications were categorized within the highest benefits level (metformin, DPP-4-inhibitors, short-acting beta-2-agonists, ACE inhibitors, beta-blockers, warfarin, non-vitamin K oral anticoagulants, nitrates and acetaminophen). Fifteen medications were included in the highest level of risks, among which warfarin and Non-vitamin K oral anticoagulants. Conclusions Medications recommended in clinical guidelines for individual diseases are generally considered positive for multimorbid older patients. Nevertheless, a non-negligible number of medications was deemed negative or very negative by our panelists. For multimorbid patients, individualizing treatment according to their preferences seems of utmost importance.

Entities:  

Keywords:  Benefits; Multimorbidity; Polypharmacy; Quality of life; Risks

Year:  2019        PMID: 31721038     DOI: 10.1007/s11096-019-00935-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  47 in total

Review 1.  Inappropriate prescribing: criteria, detection and prevention.

Authors:  Marie N O'Connor; Paul Gallagher; Denis O'Mahony
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

2.  Pharmacologic management of type 2 diabetes.

Authors:  William Harper; Maureen Clement; Ronald Goldenberg; Amir Hanna; Andrea Main; Ravi Retnakaran; Diana Sherifali; Vincent Woo; Jean-François Yale
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

3.  Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness.

Authors:  Yael Schenker; Seo Young Park; Kwonho Jeong; Jennifer Pruskowski; Dio Kavalieratos; Judith Resick; Amy Abernethy; Jean S Kutner
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

4.  Determinants of Potentially Inappropriate Medication Use among Community-Dwelling Older Adults.

Authors:  G Edward Miller; Eric M Sarpong; Amy J Davidoff; Eunice Y Yang; Nicole J Brandt; Donna M Fick
Journal:  Health Serv Res       Date:  2016-09-29       Impact factor: 3.402

5.  Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting.

Authors:  Pietro Pirina; Marco Martinetti; Claudia Spada; Elisabetta Zinellu; Rosanna Pes; Efisio Chessa; Alessandro Giuseppe Fois; Marc Miravitlles
Journal:  Respir Med       Date:  2017-07-25       Impact factor: 3.415

6.  The relationship between frailty and polypharmacy in older people: A systematic review.

Authors:  M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla
Journal:  Br J Clin Pharmacol       Date:  2018-05-03       Impact factor: 4.335

Review 7.  Categorization and association analysis of risk factors for adverse drug events.

Authors:  Lina Zhou; Anamika Paul Rupa
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

Review 8.  Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions.

Authors:  Dae Hyun Kim; Michael W Rich
Journal:  Can J Cardiol       Date:  2016-04-20       Impact factor: 5.223

9.  Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Authors:  Claus F Vogelmeier; Gerard J Criner; Fernando J Martinez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolas Roche; Roberto Rodriguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agusti
Journal:  Respirology       Date:  2017-03-07       Impact factor: 6.424

10.  Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool.

Authors:  Mohammed A Mohammed; Rebekah J Moles; Sarah N Hilmer; Lisa Kouladjian O'Donnel; Timothy F Chen
Journal:  BMJ Open       Date:  2018-01-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.